CMPS Compass Pathways Plc
Company Analysis
Latest News
🟢 Compass Pathways is trading 7.4% up today after key FDA milestones for its psilocybin therapy
Compass Pathways is trading 7.4% up at $14.30 following significant regulatory progress for its COMP360 psilocybin therapy. • The FDA accepted an...
🟢 Compass Pathways is trading 8.2% up today following FDA acceptance of PTSD trial and rolling NDA for depression
Compass Pathways is trading at $14.40 (+8.2%) in pre-market, extending a strong multi-day rebound driven by significant regulatory progress for its COMP360...
🔴 Compass Pathways is trading 5.2% down today amid biotech weakness and broader risk-off sentiment
Compass Pathways is trading at $12.94 (down 5.2%) as the biotech sector faces pressure from broader risk-off market sentiment. • No new company-specific news...
🟢 CMPS is trading 5% up today as investors reassess Phase 3 durability data after a sharp selloff
CMPS is trading 5% up at $13.64 as the stock rebounds from a sharp selloff tied to investor reaction to six-month durability results from its COMP006 Phase 3...
🔴 CMPS is trading 7.6% down today as market digests Phase 3 durability results
CMPS is trading at $12.00 (7.6% down) as investors continue to react to six-month durability results from its COMP006 Phase 3 trial in treatment-resistant...
🔴 CMPS is trading 5.3% down today on Phase 3 depression trial durability data
CMPS is trading 5.3% down at $12.16 as investors react to 26-week durability data from its Phase 3 COMP006 trial for treatment-resistant depression. • The...
🔴 CMPS makes sharp 11.1% drop
CMPS is trading at $11.41, down 11.1% versus the comparison close of $12.84 during pre-market. This is a price-movement alert; no separate company-specific...
🔴 CMPS is trading 6.5% down today after Phase 3 COMP360 durability data update
CMPS is trading 6.5% down at $12.00 as investors digest new Phase 3 COMP360 durability data for treatment-resistant depression. • The company reported...
Compass Pathways Reports Positive 26-Week Phase 3 Data for COMP360 in Resistant Depression
Compass Pathways announced positive 26-week results from its second Phase 3 trial (COMP006) for COMP360, its psilocybin treatment for treatment-resistant...
Compass Pathways Clears Its Biggest Clinical Hurdle — But Can a Psilocybin Startup Actually Capture a Billion-Dollar Depression Market?
Shares of Compass Pathways jumped 8.7% to $13.96 as investors digested what amounts to the strongest clinical validation yet for a psychedelic-based depression...
🟢 CMPS is trading 8.7% up today on successful Phase 3 results for COMP360 psilocybin therapy
CMPS is trading at $13.96 (8.7% up) after announcing successful Phase 3 results for its COMP360 psilocybin therapy in treatment-resistant depression, achieving...
🔴 CMPS is trading 5% down today on continued pullback after recent rally
CMPS is trading 5% down at $13.44 as the stock extends its pullback following a sharp multi-week rally and recent profit-taking. • The decline is attributed...
🔴 CMPS is trading 5.3% down today on profit-taking after a sharp multi-day rally
CMPS is trading 5.3% down today at $14.27 as traders appear to be taking profits following a period of strong recent gains. • The downward move comes in the...
🟢 CMPS is trading 5.8% up today on bullish analyst commentary and Phase 3 trial optimism
CMPS is trading 5.8% up at $14.37 following a fresh wave of bullish analyst commentary and growing optimism surrounding its Phase 3 COMP360 depression...
Compass Pathways Target Hiked to $20, Anticipating Phase 3 Depression Data
Canaccord Genuity raised its price target for Compass Pathways to $20.00 from $18.00. The firm maintained a Buy rating on the shares. Analysts anticipate...